Santen Pharmaceutical Co (JP:4536) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Santen Pharmaceutical Co., Ltd has reported a modest revenue increase of 3.3% for the three months ending June 30, 2024, compared to the same period last year. However, there has been a slight decrease in core net profit by 2.1%. The company has also announced a share repurchase program, which is expected to impact their earnings per share forecasts.
For further insights into JP:4536 stock, check out TipRanks’ Stock Analysis page.